Deutsche Bank Starts Ariba (ARBA) at Hold; Macro Uncertainty Clouds Near-Term Upside Potential
Get Alerts ARBA Hot Sheet
Price: $44.80 --0%
Rating Summary:
3 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 13
Rating Summary:
3 Buy, 5 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 13
Join SI Premium – FREE
Deutsche Bank initiates coverage on Ariba (NASDAQ: ARBA) with a Hold. PT $27.00.
Deutsche analyst says, "Aruba is a leading provider of wireless networking equipment for campus environments. The proliferation of mobile and portable computing devices, as well as the overall steady growth of data consumption, have led to growing demand for wireless solutions within the enterprise. We believe that Aruba currently offers the best solution for addressing this demand and should see substantial growth in coming years. However, given market uncertainty and overall macro conditions we are somewhat cautious on the company’s near term prospects."
For more ratings news on Ariba click here and for the rating history of Ariba click here.
Shares of Ariba closed at $31.68 yesterday.
Deutsche analyst says, "Aruba is a leading provider of wireless networking equipment for campus environments. The proliferation of mobile and portable computing devices, as well as the overall steady growth of data consumption, have led to growing demand for wireless solutions within the enterprise. We believe that Aruba currently offers the best solution for addressing this demand and should see substantial growth in coming years. However, given market uncertainty and overall macro conditions we are somewhat cautious on the company’s near term prospects."
For more ratings news on Ariba click here and for the rating history of Ariba click here.
Shares of Ariba closed at $31.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
- Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
- Cantor Fitzgerald Starts Incyte (INCY) at Neutral, 'JAK-ing Up Its Pipeline In Advance of a Major Patent Cliff'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!